Abstract
The paper in this issue of Free Radical Biology and Medicine titled “Pharmacologic ascorbate synergizes with gemcitabine in pre-clinical models of pancreatic cancer” by Michael G. Espey and colleagues presents a compelling case for the addition of pharmacological, i.e. high-dose, intravenous ascorbate (vitamin C, AscH−) to the standard of care for treatment of pancreatic cancer, which currently is gemcitabine at many institutions [1].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
